Tumor-TME Bipartite Landscape of PD-1/PD-L1 in Endometrial Cancers

The bipartite landscape of tumor cells and stromal cells determines a tumor’s response to treatment during disease management. In endometrial cancers (ECs), the mechanistic contribution of PD-L1/L2 and PD-1 signaling of the host’s tumor microenvironment (TME) (CAF and immune cells) in the context of the tumor cells is elusive. To understand the tumor–stroma-immune crosstalk, we studied the compartmental pattern of PD-L1/L2 and PD-1 expression in EC tissues and their matched CAFs. Over 116 surgically resected tumors (T) and the tumor-adjacent normal tissues (N) were obtained from consented unselected consecutive patients. IHC was performed in T, N-epi-thelium, and the stromal mesenchymal environment (SME; mesenchyme) in the T and N tissues. The staining intensity and distribution patterns of PD-L1/L2 and PD-1 in the FFPE sections of T and N were evaluated by a pathologist using a standard scoring system of TPS and CPS. We tested the PD-L1/L2 and PD-1 immune landscape of tumor-TME pair and normal epithelial-stromal mesenchyme pairs from patients with different grades of disease vis-à-vis their CAF PD-L1 levels. We used qRT-PCR to determine the expressions of mRNAs, while the flow cytometry and ICC determined the level of expression of proteins. We observed higher levels of PD-L1 mRNA and protein expression in primary CAFs from the resected tumor tissue compared to the tumor-adjacent normal tissues. We also determined the expression of patients’ soluble PD-L1/L2 as peripheral readouts of PD-L1/L2 and PD-1. As we evaluated the results in the context of their pathological parameters, such as grades, stages, lymphovascular invasion, percentage of myometrial invasion, and dMMR in patients, the dominance of PD-L1 expression in TME was positively correlated to the higher pathological grades of tumors, and its relationship with the dMMR. Since the neutralization of CD8-positive cytotoxic T-cells is PD-L1-dependent, our data indicate that irrespective of the PD-L1 positivity of tumor cells, the PD-L1-positive CAFs can play a critical role in bringing out an additional load of PD-L1 for an effective engagement of PD-1 within a tumor mass.

[1]  A. Obradovic Precision immunotherapy , 2023, Science.

[2]  P. De,et al.  Patient-Derived Primary Cancer-Associated Fibroblasts Mediate Resistance to Anti-Angiogenic Drug in Ovarian Cancers , 2023, Biomedicines.

[3]  Ryan D. Chow,et al.  Distinct mechanisms of mismatch repair deficiency delineate two modes of response to PD-1 immunotherapy in endometrial carcinoma. , 2022, Cancer discovery.

[4]  Do Young Hyeon,et al.  PD-L1-directed PlGF/VEGF blockade synergizes with chemotherapy by targeting CD141+ cancer-associated fibroblasts in pancreatic cancer , 2022, Nature Communications.

[5]  X. Matías-Guiu,et al.  Facts and hopes in immunotherapy of endometrial cancer. , 2022, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  P. De,et al.  Bête Noire of Chemotherapy and Targeted Therapy: CAF-Mediated Resistance , 2022, Cancers.

[7]  A. Tinker,et al.  Safety and antitumor activity of dostarlimab in patients with advanced or recurrent DNA mismatch repair deficient/microsatellite instability-high (dMMR/MSI-H) or proficient/stable (MMRp/MSS) endometrial cancer: interim results from GARNET—a phase I, single-arm study , 2022, Journal for ImmunoTherapy of Cancer.

[8]  X. Guan,et al.  Near‐Infrared Responsive Membrane Nanovesicles Amplify Homologous Targeting Delivery of Anti‐PD Immunotherapy against Metastatic Tumors , 2021, Advanced healthcare materials.

[9]  Songfa Zhang,et al.  PD-L1 Expression in Endometrial Serous Carcinoma and Its Prognostic Significance , 2021, Cancer management and research.

[10]  Chen Liang,et al.  Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives , 2021, Molecular Cancer.

[11]  P. De,et al.  Cancer-Associated Fibroblast Functions as a Road-Block in Cancer Therapy , 2021, Cancers.

[12]  A. Jennifer,et al.  Cancer-Associated Fibroblasts in Conversation with Tumor Cells in Endometrial Cancers: A Partner in Crime , 2021, International journal of molecular sciences.

[13]  Qin Luo,et al.  Exosomal lncRNA NEAT1 from cancer-associated fibroblasts facilitates endometrial cancer progression via miR-26a/b-5p-mediated STAT3/YKL-40 signaling pathway , 2021, Neoplasia.

[14]  R. Scolyer,et al.  Programmed death ligand-1 (PD-L1) as a predictive marker for immunotherapy in solid tumours: a guide to immunohistochemistry implementation and interpretation. , 2020, Pathology.

[15]  M. Stoler,et al.  PD-L1 and Mismatch Repair Status in Uterine Carcinosarcomas , 2020, International journal of gynecological pathology : official journal of the International Society of Gynecological Pathologists.

[16]  Joel s. Brown,et al.  The Contribution of Evolutionary Game Theory to Understanding and Treating Cancer , 2020, Dynamic Games and Applications.

[17]  A. Tinker,et al.  Clinical Activity and Safety of the Anti–Programmed Death 1 Monoclonal Antibody Dostarlimab for Patients With Recurrent or Advanced Mismatch Repair–Deficient Endometrial Cancer , 2020, JAMA oncology.

[18]  W. McCluggage,et al.  Correlation of PD-L1 expression with immunohistochemically determined molecular profile in endometrial carcinomas , 2020, Virchows Archiv.

[19]  D. Tuveson,et al.  DIVERSITY AND BIOLOGY OF CANCER-ASSOCIATED FIBROBLASTS. , 2020, Physiological reviews.

[20]  N. Zhang,et al.  Extracellular vesicle encapsulated microRNA-320a inhibits endometrial cancer by suppression of the HIF1α/VEGFA axis. , 2020, Experimental cell research.

[21]  T. Bosse,et al.  PARP and PD-1/PD-L1 checkpoint inhibition in recurrent or metastatic endometrial cancer. , 2020, Critical reviews in oncology/hematology.

[22]  A. Mills,et al.  β-catenin and PD-L1 expression in mismatch repair deficient endometrial carcinomas , 2020, International Journal of Gynecological Cancer.

[23]  Yuanting Gu,et al.  Cancer-associated fibroblasts-derived exosomes suppresses immune cell function in breast cancer via miR-92/PD-L1 pathway , 2020 .

[24]  E. Schmidt,et al.  Lenvatinib Plus Pembrolizumab in Patients With Advanced Endometrial Cancer , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[25]  T. Satoh,et al.  PD-L1 and CD4 are independent prognostic factors for overall survival in endometrial carcinomas , 2020, BMC Cancer.

[26]  L. Diaz,et al.  Efficacy of Pembrolizumab in Patients With Noncolorectal High Microsatellite Instability/Mismatch Repair-Deficient Cancer: Results From the Phase II KEYNOTE-158 Study. , 2020, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[27]  P. Vahteristo,et al.  PD-L1 Expression in Endometrial Carcinoma Cells and Intratumoral Immune Cells , 2019, The American journal of surgical pathology.

[28]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[29]  A. Chinnaiyan,et al.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[30]  J. Taube,et al.  PD-L1 on host cells is essential for PD-L1 blockade–mediated tumor regression , 2018, The Journal of clinical investigation.

[31]  David Basanta,et al.  Fibroblasts and Alectinib switch the evolutionary games played by non-small cell lung cancer , 2017, Nature Ecology & Evolution.

[32]  Freeman,et al.  PD-L1 on tumor cells is sufficient for immune evasion in immunogenic tumors and inhibits CD8 T cell cytotoxicity , 2017, The Journal of experimental medicine.

[33]  A. Mills,et al.  PD-L1 Expression in Mismatch Repair-deficient Endometrial Carcinomas, Including Lynch Syndrome-associated and MLH1 Promoter Hypermethylated Tumors , 2017, The American journal of surgical pathology.

[34]  Robert R Yauch,et al.  Tumour and host cell PD-L1 is required to mediate suppression of anti-tumour immunity in mice , 2017, Nature Communications.

[35]  I. S. Omar,et al.  Cancer-associated fibroblasts promote endometrial cancer growth via activation of interleukin-6/STAT-3/c-Myc pathway. , 2016, American journal of cancer research.

[36]  D. Olive,et al.  A novel regulation of PD-1 ligands on mesenchymal stromal cells through MMP-mediated proteolytic cleavage , 2015, Oncoimmunology.

[37]  Y. Woo,et al.  Cancer-Associated Fibroblasts Promote Proliferation of Endometrial Cancer Cells , 2013, PloS one.

[38]  A. Chinnaiyan,et al.  Host expression of PD-L1 determines efficacy of PD-L1 pathway blockade-mediated tumor regression. , 2018, The Journal of clinical investigation.